. 2013 Nov;57(11):5315–5319. doi: 10.1128/AAC.01059-13

Table 1.

In vitro antibacterial activity of antibiotic PM181104

Organism and resistance profile^a (no. of test strains)	MIC range (μg/ml)	MIC₅₀ (μg/ml)	MIC₉₀ (μg/ml)
S. aureus MRSA (67)	0.008–2.048	0.032	0.064
S. aureus MSSA (48)	0.008–2.048	0.032	0.064
S. aureus MRSA, inducible ERY^r (1)	1.024
S. aureus carrying cfr (1)	1.024
S. aureus LZD^r (6)	0.250–0.500
S. epidermidis (23)	0.008–1.024	0.064	0.128
E. faecium VSE (12)	0.008–0.032	0.008	0.016
E. faecalis VRE (12)	0.064–1.024	0.064	0.128
E. faecalis VSE (30)	0.002–16	0.008	0.016
E. faecium VRE (5)	0.008–0.008
E. faecium D^r (3)	0.128–0.256
E. faecalis LZD^r (5)	0.128–0.256
E. faecalis GM^r (6)	0.128–0.512
E. faecalis D^r (3)	0.256–0.512
Clinical VRE species (16)	0.004–0.128	0.008	0.064
Bacillus spp. (6)	0.004–0.016

MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive S. aureus; ERY^r, erythromycin resistant; LZD^r, linezolid resistant; VRE, vancomycin-resistant enterococci; VSE, vancomycin-susceptible enterococci; D^r, doxycycline-resistant; GM^r, gentamicin-resistant; cfr, gene that mediates the resistance phenotype (includes resistance to oxazolidinones, pleuromutilins-phenicols, lincosamides, streptogramin A antibiotics, etc.).